Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Laurent Chanroux
  • November 11, 2014
  • Articles

Physicians predict the impact new molecules will have on the EU psoriasis market

Physicians predict the impact new molecules will have on the EU psoriasis market

With several new molecules expected to launch onto the psoriasis market over the next 12 months, we recently asked our panel of 200 EU-based dermatologists the impact this may have on their future prescribing behaviour.

Utilising our panel of 200 EU based dermatologists, our results reveal that 74% of physicians are aware of new classes and/or drugs in development for the treatment of Psoriasis (PsO) without prompting. IL-17 inhibitors were the most commonly mentioned drugs cited by 75% of respondents, followed by JAK-inhibitors and PDE-inhibitors. However, when physicians were prompted about their familiarity with key pipeline agents they reported low scores overall, suggesting that more awareness and improvement of physicians’ knowledge of these late stage compounds are needed to achieve growth in the market.  

read more »

Maximising uptake of biosimilars in an evolving market

Our client was developing biosimilars of two biologic drugs and wanted to understand the likely market potential for their assets.

 

read more »